A man has died after being hit by a car in Somerset, police have said. Avon and Somerset Police officers were called to the ...

Car insurance premiums rose 25% between 2023 and 2024. The surge has been fueled by several factors, according to the ...

Automakers routinely use concept vehicles to gauge customer interest in a design or show the future direction of a vehicle or ...

One resident from Morris County resident reported that he had seen hundreds of the “drones” flying for hours at a time for ...

The auto industry is highly sensitive to supply and demand. When there’s more supply than demand, dealers are more willing to ...

A stolen car chase led to a four-vehicle crash on Rochester's north side Tuesday after 4 p.m. near the intersection of Norton ...

12月2日，CAR-T细胞疗法概念上涨2.39%，今日主力资金流入1.57亿元，概念股20只上涨，2只下跌。 主力资金净流入居前的分别为药明康德（1.45亿元）、海南海药（6855.11万元）、智飞生物（3071.63万元）、香雪制药（2043.58万元）、中源协和（800.03万元）。

在当今医疗科技飞速发展的时代，CAR-T细胞疗法作为一种新兴的癌症治疗方式，因其高效和灵活性备受关注。然而，标价百万的CAR-T药物却在国家医保谈判中接连遭遇"折戟"，这背后究竟隐含着怎样的故事？

每年一度的医保谈判始终是业界翘首以待的盛事。自2018年国家医保局正式成立以来，国家医保局通过将创新药物以公允的价格及时纳入医保目录，以及支持其临床应用的加速等措施，极大地推动了创新药物的发展进程。

非霍奇金淋巴瘤（NHL）是一组淋巴造血系统恶性肿瘤的统称，其中以弥漫大B细胞淋巴瘤（DLBCL）最为常见。DLBCL病理类型复杂，临床亚型众多、可表现出不同的预后结局。对化疗敏感的复发/难治性DLBCL患者进行大剂量化疗后自体造血干细胞移植（HD-A ...